Biotech RadarJobs updated

COMPANY

Merck & Co., Inc.

HQ: Rahway, NJ source · merck.com ↗ · Mid-Atlantic

FDA-approved therapeutic company FDA-cleared device company Clinical Phase 3

Also known as EyeBiotech Ltd., Merck, Merck Sharp & Dohme LLC · 1,137 open jobs · last seen Oct 23, 2026 · 55 sources

No verified company description yet.

Keywords: Non-small Cell Lung Cancer Diabetic Retinopathy Macular Edema Lymphoma, Large B-Cell, Diffuse Prostatic Neoplasms Follicular Lymphoma Diffuse Large B-Cell Lymphoma Bladder Cancer Hematologic Malignancies B-cell Acute Lymphoblastic Leukemia Small Cell Lung Cancer Extensive Stage Pulmonary Sarcoidosis Castration-Resistant Prostatic Cancer Metastasis Prostate Cancer Breast Neoplasms Non-Hodgkin Lymphoma Early Alzheimer's Disease Malignant Neoplam DLBCL Pulmonary Arterial Hypertension Chronic Lymphocytic Leukaemia Small Lymphocytic Lymphoma Esophageal Squamous Cell Carcinoma Gastroesophageal Junction Gastroesophageal Adenocarcinoma Esophageal Neoplasms Esophageal Cancer Neoplasm Malignant Heterozygous Familial Hypercholesterolemia Colon Adenocarcinoma Rectal Adenocarcinoma Lung Neoplasm HIV-1 HIV Infection Pain Management Pheochromocytoma/Paraganglioma Pancreatic Neuroendocrine Tumor Von Hippel-Lindau Disease

Profile checked Oct 10, 2026

1,137Open jobs1,369Trials (company is sponsor)4NIH grants

Hiring

TitleLocation (from posting)Employer postedFirst seen
Sr. Specialist, AI EngineeringHyderabad, IndiaOct 23, 2026Oct 8, 2026
Senior Specialist, Business Insights & AnalyticsMumbai, IndiaOct 23, 2026Oct 8, 2026
Coordinateur Administration de Projets (H/F/D) - CDD 6 moisParis, FranceOct 23, 2026Oct 7, 2026
Senior Specialist , Technology PartnershipMumbai, IndiaOct 23, 2026Oct 7, 2026
R&D Oncology Japan Clinical Director (Non-MD)JPN - Tokyo - ChiyodaOct 23, 2026Oct 7, 2026

See all 1,137 jobs

Trial and FDA signals

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

  1. Trial start Phase 2: DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg source ↗
  2. Trial start Phase 1: A Clinical Trial of MK-6916 With Midazolam and Rosuvastatin in Healthy Participants (MK-6916-012) source ↗
  3. Trial start Phase 2: A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007) source ↗
  4. Trial start Phase 2: A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016) source ↗
  5. Trial start Phase 2: A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) source ↗
  6. Trial start Phase 2: A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010) source ↗
  7. Trial start Phase 2: A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) source ↗
  8. Board tracked Radar started tracking this company’s job board (1,137 open jobs at last check). source ↗
  9. Trial start Phase 3: A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005) source ↗
  10. Trial start Phase 3: A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) source ↗
  11. Trial start Phase 1: A Clinical Trial of MK-1403 in Healthy Participants (MK-1403-007) source ↗
  12. Trial start Phase 2/Phase 3: A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) source ↗
  13. Trial start Phase 3: A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) source ↗
  14. Trial start Phase 1: Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001) source ↗
  15. Trial start Phase 2/Phase 3: A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) source ↗
  16. Trial start Phase 3: A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) source ↗
  17. Trial start Phase 1/Phase 2: A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) source ↗
  18. Trial start Phase 3: A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) source ↗
  19. Trial start Phase 3: MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) source ↗
  20. Trial start Phase 1/Phase 2: A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) source ↗
  21. Trial start Phase 2: A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) source ↗
  22. Trial start Phase 3: A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) source ↗
  23. Trial start Phase 2/Phase 3: A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029) source ↗
  24. Trial start Phase 2: A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) source ↗
  25. Trial start Phase 3: A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) source ↗

Showing 25 of 51 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 1,137

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Sr. Specialist, AI EngineeringHyderabad, IndiaOct 23, 2026Oct 8, 2026Not stated
Senior Specialist, Business Insights & AnalyticsMumbai, IndiaOct 23, 2026Oct 8, 2026Senior
Coordinateur Administration de Projets (H/F/D) - CDD 6 moisParis, FranceOct 23, 2026Oct 7, 2026Mid
Senior Specialist , Technology PartnershipMumbai, IndiaOct 23, 2026Oct 7, 2026Not stated
R&D Oncology Japan Clinical Director (Non-MD)JPN - Tokyo - ChiyodaOct 23, 2026Oct 7, 2026Senior
Director Strategic Planning2 locations, including Rahway, New Jersey, USAOct 23, 2026Oct 17, 2026Not stated
Specialist, SAP Data AnalyticsHyderabad, IndiaOct 23, 2026Oct 17, 2026Not stated
Sr. Key Account Manager, RetailChengdu, ChinaOct 23, 2026Oct 20, 2026Not stated
Pharm Technician (WDA)SingaporeOct 23, 2026Oct 20, 2026Not stated
Assoc. Spclst, Engineering (WDA)SingaporeOct 23, 2026Oct 23, 2026Not stated
AtR General Ledger Specialist (Fixed Term)Prague, CzechiaOct 23, 2026Oct 23, 2026Not stated
Senior Manager, ServiceNow Senior Developer - Operational TechnologyHyderabad, IndiaOct 23, 2026Oct 23, 2026Not stated
Sr. Spclst, Quality Assurance (Upstream)IRL - Meath - DunboyneOct 23, 2026Oct 23, 2026Not stated
Vaccine Customer Specialist (Multiple Locations)Warsaw, PolandOct 23, 2026Oct 23, 2026Not stated
Intern – HBO/WO Business administration or Data Analytics – Intellectual PropertyNLD - North Brabant - BoxmeerOct 23, 2026Oct 23, 2026Not stated
Sales Team Leader (North Central Poland)POL - Poland - PolandOct 23, 2026Oct 23, 2026Not stated
Specialist, AI EngineeringHyderabad, IndiaOct 23, 2026Oct 23, 2026Not stated
Associate Director, FPP Engagement & Enablement Lead, AP12 locations, including Singapore Boulevard Towers, Singapore, SGPOct 23, 2026Oct 23, 2026Not stated
Pharmaceutical Information SpecialistCHN - Guangzhou - TianheOct 23, 2026Oct 23, 2026Not stated
Senior Professional Sales SpecialistTWN - Taipei - Taipei CityOct 23, 2026Oct 23, 2026Not stated
Associate Director, Drug Product, Quality AssuranceWilmington, DEOct 22, 2026Oct 8, 2026Senior
Senior Specialist Engineering (Onsite)USA - New Jersey - RahwayOct 22, 2026Oct 8, 2026Senior
Associate Director Regional Market Access2 locations, including North Wales Upper Gwynedd, Pennsylvania, USAOct 22, 2026Oct 7, 2026Senior
Spclst, Scitara Technical AnalystHyderabad, IndiaOct 22, 2026Oct 7, 2026Mid
Associate Director, Quality ControlIRL - Carlow - CarlowOct 22, 2026Oct 7, 2026Senior
Bioprocess TechnicianNLD - Utrecht - De BiltOct 22, 2026Oct 7, 2026Entry
Post Doc Fellow-Immunogenicity PredictionUSA - Pennsylvania - West PointOct 22, 2026Oct 7, 2026Not stated
Sr. Spclst, MarketingNorth Wales, PAOct 22, 2026Oct 7, 2026Not stated
Rare Disease Account Specialist, PAH - Colorado2 locations, including Denver, Colorado, USAOct 22, 2026Oct 7, 2026Not stated
2027 Future Talent Program - Global Supplier Management Group Supplier Development & Performance Management - Intern2 locations, including West Point, Pennsylvania, USAOct 22, 2026Oct 7, 2026Not stated
Senior Operator Visuele InspectieNLD - North Brabant - BoxmeerOct 22, 2026Oct 7, 2026Senior
Operational Coach (Start-up Phase)NLD - North Brabant - BoxmeerOct 22, 2026Oct 7, 2026Mid
Senior Validatie/Kwalificatie EngineerNLD - North Brabant - BoxmeerOct 22, 2026Oct 7, 2026Senior
Operator (Dagdienst)NLD - North Brabant - BoxmeerOct 22, 2026Oct 7, 2026Entry
Director, Global Oncology Marketing - Prostate Cancer2 locations, including Rahway, New Jersey, USAOct 22, 2026Oct 9, 2026Senior
Clinical ProgrammerSan Jose, Costa RicaOct 22, 2026Oct 14, 2026Not stated
Associate Director, U.S. Account Management StrategyNorth Wales, PAOct 22, 2026Oct 17, 2026Not stated
Senior Director, Clinical Science, Infectious Disease, Hybrid4 locations, including Rahway, New Jersey, USAOct 22, 2026Oct 17, 2026Not stated
HIV Customer Representative - New Orleans Territory Mirror2 locations, including North Wales Upper Gwynedd, Pennsylvania, USAOct 22, 2026Oct 17, 2026Not stated
Senior. Specialist, Software Engineering (CIAM)2 locations, including Hyderabad Hitec City Raidurg, Telangana, INDOct 22, 2026Oct 17, 2026Not stated
Senior Specialist, Platform Architect (CIAM)2 locations, including Hyderabad Hitec City Raidurg, Telangana, INDOct 22, 2026Oct 17, 2026Not stated
Senior Specialist, Technical Product ManagementHyderabad, IndiaOct 22, 2026Oct 17, 2026Not stated
Associate Director, Clinical Research Associate ManagerMumbai, IndiaOct 22, 2026Oct 17, 2026Not stated
Functional Area Geography Associate Director, GDMS Clinical Data ManagementWarsaw, PolandOct 22, 2026Oct 17, 2026Not stated
Associate Specialist, Clinical Data Management2 locations, including West Point, Pennsylvania, USAOct 22, 2026Oct 23, 2026Not stated
Senior Technician, OperationsMillsboro, DEOct 22, 2026Oct 23, 2026Not stated
Associate Technician, OperationsUSA - Texas - IrvingOct 22, 2026Oct 23, 2026Not stated
Technician, OperationsMillsboro, DEOct 22, 2026Oct 23, 2026Not stated
Senior Medical Writer, Safety Support Services3 locations, including Bogot Colpatria, Cundinamarca, COLOct 22, 2026Oct 23, 2026Not stated
Senior Technician (Process), OperationsUSA - North Carolina - WilsonOct 22, 2026Oct 23, 2026Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

All 1,137 jobs →

Clinical trials (lead sponsor) Showing 50 of 1,369

RecordTitlePhaseStatusStartPrimary completion
NCT07705555A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)Phase 3RecruitingAug 27, 2026Oct 31, 2028 (estimated)
NCT07785609A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)Phase 2RecruitingOct 9, 2026Sep 30, 2031 (estimated)
NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Phase 1/Phase 2RecruitingJan 29, 2026Nov 29, 2030 (estimated)
NCT07513376A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)Phase 3RecruitingMay 4, 2026Aug 22, 2034 (estimated)
NCT07705607A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)Phase 3RecruitingSep 25, 2026Nov 30, 2028 (estimated)
NCT07554339A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)Phase 3RecruitingJun 18, 2026Dec 15, 2032 (estimated)
NCT07867938A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)Phase 2Not yet recruitingNov 6, 2026Oct 5, 2029 (estimated)
NCT07677163A Clinical Trial of MK-1403 in Healthy Participants (MK-1403-007)Phase 1CompletedAug 14, 2026Oct 5, 2026 (actual)
NCT06863272A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)Phase 1/Phase 2RecruitingJul 3, 2025Oct 1, 2031 (estimated)
NCT06890884A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)Phase 2RecruitingApr 11, 2025Dec 13, 2027 (estimated)
NCT06623409Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).Phase 1RecruitingNov 12, 2024May 31, 2028 (estimated)
NCT06925737A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)Phase 3RecruitingMay 13, 2025Jun 26, 2028 (estimated)
NCT07060807A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)Phase 3RecruitingJul 21, 2025Jul 14, 2033 (estimated)
NCT07519772A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)Phase 1/Phase 2RecruitingMay 3, 2026Jul 1, 2030 (estimated)
NCT07033494A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)Phase 2RecruitingJul 16, 2025Apr 30, 2029 (estimated)
NCT07793942A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)Phase 2Not yet recruitingOct 27, 2026Sep 26, 2028 (estimated)
NCT05139017A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)Phase 2/Phase 3RecruitingJan 14, 2022Sep 24, 2027 (estimated)
NCT03924856Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)Phase 3CompletedJun 13, 2019Jan 26, 2026 (actual)
NCT07218029A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)Phase 3Active, not recruitingMay 12, 2021Dec 7, 2028 (estimated)
NCT07709000A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)Phase 2Not yet recruitingOct 9, 2026Nov 16, 2033 (estimated)
NCT07570173A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)Phase 2/Phase 3RecruitingMay 18, 2026Oct 18, 2033 (estimated)
NCT07634471A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)Phase 2/Phase 3RecruitingJun 22, 2026Jul 23, 2032 (estimated)
NCT05067283A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)Phase 1RecruitingDec 17, 2021Feb 25, 2030 (estimated)
NCT05319730A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)Phase 1/Phase 2RecruitingMay 16, 2023Jun 11, 2027 (estimated)
NCT07190248A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)Phase 3RecruitingOct 8, 2025Dec 7, 2029 (estimated)
NCT06469944Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)Phase 1/Phase 2RecruitingSep 20, 2024Sep 12, 2029 (estimated)
NCT07209111A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)Phase 2RecruitingDec 4, 2025Apr 9, 2032 (estimated)
NCT07058077A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)Phase 2/Phase 3RecruitingAug 21, 2025Dec 4, 2033 (estimated)
NCT07431827MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)Phase 3RecruitingMar 18, 2026Oct 26, 2039 (estimated)
NCT06731907A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)Phase 2RecruitingMar 30, 2025Mar 12, 2032 (estimated)
NCT03486873Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)Phase 3RecruitingAug 21, 2018Aug 4, 2043 (estimated)
NCT06997497A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)Phase 3RecruitingJul 16, 2025Mar 28, 2029 (estimated)
NCT06345729A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)Phase 3RecruitingMay 24, 2024Jan 24, 2028 (estimated)
NCT06780098Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)Phase 2RecruitingMay 28, 2025Mar 2, 2032 (estimated)
NCT07862621A Clinical Trial of MK-6916 With Midazolam and Rosuvastatin in Healthy Participants (MK-6916-012)Phase 1Not yet recruitingNov 30, 2026Feb 9, 2027 (estimated)
NCT07862569DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kgPhase 2Not yet recruitingDec 23, 2026Sep 24, 2029 (estimated)
NCT04956692Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)Phase 3CompletedAug 5, 2021Apr 4, 2023 (actual)
NCT07862595A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)Phase 2Not yet recruitingNov 23, 2026Jun 10, 2027 (estimated)
NCT04924075Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)Phase 2RecruitingAug 12, 2021Nov 18, 2032 (estimated)
NCT06843447A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)Phase 1/Phase 2RecruitingApr 15, 2025Mar 27, 2029 (estimated)
NCT06395103Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)Phase 1/Phase 2RecruitingAug 16, 2024Mar 31, 2029 (estimated)
NCT06841354A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Phase 3RecruitingMar 16, 2025May 18, 2030 (estimated)
NCT06941272A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)Phase 1/Phase 2RecruitingMay 26, 2025Dec 30, 2030 (estimated)
NCT07419295A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)Phase 3RecruitingApr 23, 2026Jul 27, 2029 (estimated)
NCT06136650A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)Phase 3RecruitingDec 18, 2023May 10, 2028 (estimated)
NCT06353386Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)Phase 1/Phase 2RecruitingMay 20, 2024Jan 15, 2029 (estimated)
NCT06979596A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)Phase 2RecruitingAug 11, 2025Nov 4, 2027 (estimated)
NCT06818643A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)Phase 1/Phase 2RecruitingMar 25, 2025Mar 7, 2031 (estimated)
NCT07600749Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)Phase 1RecruitingJun 18, 2026Oct 4, 2029 (estimated)
NCT06428409A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)Phase 1/Phase 2RecruitingJun 20, 2024Oct 16, 2029 (estimated)

NIH awards 4

Annual award amounts. Total $3.1M.

Connect

See your connections at Merck on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-14

Feedback